We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

116 hedge funds and large institutions have $123M invested in G1 Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more call options, than puts

Call options by funds: $550K | Put options by funds: $341K

50% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 24

12% more funds holding

Funds holding: 104 → 116 (+12)

7% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 30

57% less capital invested

Capital invested by funds: $287M → $123M (-$164M)

Holders
116
Holders Change
+12
Holders Change %
+11.54%
% of All Funds
1.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
36
Increased
32
Reduced
30
Closed
24
Calls
$550K
Puts
$341K
Net Calls
+$209K
Net Calls Change
-$537K

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$6.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$4.56M
3
Millennium Management
Millennium Management
New York
+$4.18M
4
Marshall Wace
Marshall Wace
United Kingdom
+$3.04M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.93M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$12.1M
2
PBA
Paradigm Biocapital Advisors
New York
-$11M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$4.32M
4
CSS
Cubist Systematic Strategies
Connecticut
-$3.11M
5
EI
EAM Investors
California
-$2.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
26
Laurion Capital Management
New York
$1.09M +$1.68M +200,000 New
NIM
27
Needham Investment Management
New York
$999K +$419K +50,000 +37%
Charles Schwab
28
Charles Schwab
California
$994K +$18.7K +2,227 +1%
State Street
29
State Street
Massachusetts
$976K -$12.1M -1,438,645 -89%
Voloridge Investment Management
30
Voloridge Investment Management
Florida
$820K -$1.49M -177,870 -54%
BC
31
BIT Capital
Germany
$748K +$960K +114,547 +494%
Jane Street
32
Jane Street
New York
$717K +$423K +50,496 +62%
Northern Trust
33
Northern Trust
Illinois
$639K +$208K +24,782 +27%
Ameriprise
34
Ameriprise
Minnesota
$632K -$9.88K -1,179 -1%
E
35
Ergoteles
New York
$629K +$970K +115,751 New
Tudor Investment Corp
36
Tudor Investment Corp
Connecticut
$612K +$240K +28,627 +34%
Bank of Montreal
37
Bank of Montreal
Ontario, Canada
$596K +$916K +109,339 New
HF
38
HRT Financial
New York
$582K +$899K +107,275 New
Wellington Management Group
39
Wellington Management Group
Massachusetts
$572K +$28.5K +3,396 +3%
Swiss National Bank
40
Swiss National Bank
Switzerland
$562K +$867K +103,500 New
XT
41
XTX Topco
Cayman Islands
$555K +$732K +87,345 +585%
Jacobs Levy Equity Management
42
Jacobs Levy Equity Management
New Jersey
$505K -$79.4K -9,472 -9%
CWM
43
Curi Wealth Management
North Carolina
$440K +$187K +22,272 +38%
Mackenzie Financial
44
Mackenzie Financial
Ontario, Canada
$421K +$649K +77,450 New
CSS
45
Cubist Systematic Strategies
Connecticut
$398K -$3.11M -371,510 -84%
Point72 Asset Management
46
Point72 Asset Management
Connecticut
$367K +$567K +67,600 New
LCM
47
Landscape Capital Management
New Jersey
$305K +$470K +56,117 New
Squarepoint
48
Squarepoint
New York
$268K +$9.49K +1,133 +2%
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$257K -$3.11K -371 -0.8%
SG Americas Securities
50
SG Americas Securities
New York
$255K +$72.8K +8,684 +23%
1
2
3 4 5

GTHX Hedge Fund Activity: Q4 2022 in Review

116 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q4 2022, worth a combined $123M — down 57% from $287M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new GTHX positions and 24 closed out — a net gain of 12 holders — while 32 added to existing stakes and 30 trimmed.

The largest buyer was Woodline Partners, adding an estimated $6.3M. The largest seller was State Street, cutting an estimated $12.1M.

  • 116 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q4 2022, up from 104 in Q3 2022.
  • Funds reported $123M of G1 Therapeutics, Inc. Common Stock stock for Q4 2022, down 57% quarter-over-quarter.
  • 36 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q4 2022 and 24 closed out, a net change of +12 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q4 2022 was Woodline Partners, an estimated $6.3M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q4 2022 was State Street, an estimated $12.1M sold.

Based on aggregated 13F filings for Q4 2022.